Cancer related complications
Independent studies have suggested that Erythropoiesis-stimulating agents such as EPO have demonstrated efficacy
in the treatment of cancer-related anaemia. These trials have demonstrated that the use of recombinant human EPO
to treat anemia in cancer patients increases haemoglobin levels, reduces transfusion requirements and improves QOL, predominantly by reducing fatigue1. Moreover, EPO therapy may also improve cognitive function in patients
Invasive fungal infections are one of the leading causes of morbidity and mortality in cancer patients3.
Clark O, Adams JR, Bennett CL et al.: Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2, 23 (2002).
Beutel G, Ganser A: Risks and benefits of erythropoiesis-stimulating agents in cancer management. Semin. Hematol. 44, 157–165 (2007).
Viscoli C, Castagnola E, Machetti M.: Antifungal treatment in patients with cancer, J Intern Med Suppl. (1997).